Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Berneman

Showing results (211-220 of 219) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 219 results.
Stem Cells (Dayton, Ohio)|March 19, 2016
In Vivo Interleukin-13-Primed Macrophages Contribute to Reduced Alloantigen-Specific T Cell Activation and Prolong Immunological Survival of Allogeneic Mesenchymal Stem Cell ImplantsChloé J Hoornaert, Evi Luyckx, Kristien Reekmans, et al.
Cancer Immunology, Immunotherapy : CII|April 13, 2015
Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functionsYannick Willemen, Johan M J Van den Bergh, Eva Lion, et al.
Frontiers in Immunology|March 14, 2022
Overexpression of FcεRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom AnaphylaxisJessy Elst, Leander P De Puysseleyr, Didier G Ebo, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2010
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationViggo F Van Tendeloo, Ann Van de Velde, Ann Van Driessche, et al.
Journal of Neuroinflammation|August 17, 2019
Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNAJudith Derdelinckx, María José Mansilla, Maxime De Laere, et al.
Oncoimmunology|July 8, 2022
Trial watch: Dendritic cell (DC)-based immunotherapy for cancerRaquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, et al.
Blood|August 24, 2017
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemiaSébastien Anguille, Ann L Van de Velde, Evelien L Smits, et al.
Journal of Hematology & Oncology|March 20, 2025
Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcomeZwi N Berneman, Maxime De Laere, Paul Germonpré, et al.
Journal of Hematology & Oncology|January 24, 2025
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcomeZwi N Berneman, Maxime De Laere, Paul Germonpré, et al.
Pageof 22

Showing results (211-220 of 219) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 219 results.
Stem Cells (Dayton, Ohio)|March 19, 2016
In Vivo Interleukin-13-Primed Macrophages Contribute to Reduced Alloantigen-Specific T Cell Activation and Prolong Immunological Survival of Allogeneic Mesenchymal Stem Cell ImplantsChloé J Hoornaert, Evi Luyckx, Kristien Reekmans, et al.
Cancer Immunology, Immunotherapy : CII|April 13, 2015
Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functionsYannick Willemen, Johan M J Van den Bergh, Eva Lion, et al.
Frontiers in Immunology|March 14, 2022
Overexpression of FcεRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom AnaphylaxisJessy Elst, Leander P De Puysseleyr, Didier G Ebo, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2010
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationViggo F Van Tendeloo, Ann Van de Velde, Ann Van Driessche, et al.
Journal of Neuroinflammation|August 17, 2019
Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNAJudith Derdelinckx, María José Mansilla, Maxime De Laere, et al.
Oncoimmunology|July 8, 2022
Trial watch: Dendritic cell (DC)-based immunotherapy for cancerRaquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, et al.
Blood|August 24, 2017
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemiaSébastien Anguille, Ann L Van de Velde, Evelien L Smits, et al.
Journal of Hematology & Oncology|March 20, 2025
Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcomeZwi N Berneman, Maxime De Laere, Paul Germonpré, et al.
Journal of Hematology & Oncology|January 24, 2025
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcomeZwi N Berneman, Maxime De Laere, Paul Germonpré, et al.
Pageof 22